IP Library Granted Patent US 12,059,482
Granted Patent B2
US 12,059,482 · App. 17/127,754 · Granted Aug 13, 2024

Activity-based probe compounds, compositions, and methods of use

Inventors: Matthew S. Bogyo (Redwood City, CA); Martijn Verdoes (Nijmegen, NL)
Assignee: The Board of Trustees of the Leland Stanford Junior University
A61K49/0052A61K49/0032A61K49/0034
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,059,482
App. No.
17/127,754
Granted
Aug 13, 2024
Kind
B2
Abstract

Activity-based probe compounds for use in labeling a cysteine protease are provided. The compounds are targeted to the protease through a specific targeting element. The compounds additionally include a detectable element, such as a fluorescent label, a radiolabel, or a chelator. In some cases, the compounds additionally include a quenching element that is released upon reaction with the protease. Also provided are compositions comprising the compounds and methods for using the compounds, for example in labeling a protease in an animal and in visualizing a tumor in an animal.

Claims (40)

1. A compound for use in labeling a protease having the formula (II):

L 1 is a linker;

AA 1 is an amino acid side chain;

U is O, NH, or S;

R 1 is alkyl, alkenyl, alkynyl, aryl, aralkyl, heteroaryl, heteroaralkyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, or a protecting group, and is optionally substituted with 1 to 3 A groups;

each A is independently alkyl, alkenyl, alkynyl, alkoxy, alkanoyl, alkylamino, aryl, aryloxy, arylamino, aralkyl, aralkoxy, aralkanoyl, aralkamino, heteroaryl, heteroaryloxy, heteroarylamina, heteroaralkyl, heteroaralkoxy, heteroaralkanoyl, heteroaralkamino, cycloalkyl, cycloalkenyl, cycloalkylalkyl, cycloalkoxy, cycloalkanoyl, cycloalkamino, heterocyclyl, heterocyclyloxy, heterocyclylamino, heterocyclylalkyl, heterocyclylalkoxy, heterocyclylalkanoyl, heterocyclylalkamino, hydroxyl, thio, amino, alkanoylamino, aroylamino, aralkanoylamino, alkylcarboxy, carbonate, carbamate, guanidinyl, urea, halo, trihalomethyl, cyano, nitro, phosphoryl, sulfonyl, sulfonamido, or azido;

L 3 is a linker; and

Q comprises a quencher,

wherein D comprises a benzoindole dye having the structure:

wherein o is an integer from 1 to 4;

R 2 is a C 2 -C 8 alkyl group, substituted with a sulfonate or carbonate;

each R 3 is independently a C 1 -C 6 alkyl group; and

L 4 is an optionally substituted alkyl linker, wherein each carbon atom is optionally replaced with a heteroatom.

2. The compound of claim 1 , wherein the benzoindole dye has the structure:

3. The compound of claim 1 , wherein the benzoindole dye has the structure:

4. The compound of claim 1 , wherein L 1 is an optionally substituted alkyl linker, wherein each carbon atom is optionally replaced with a heteroatom.

5. The compound of claim 1 , wherein AA 1 is an aralkyl amino acid side chain, optionally substituted with 1 to 3 A groups.

6. The compound of claim 1 , wherein the U is O.

7. The compound of claim 1 , wherein L 3 is an optionally substituted alkyl linker, wherein each carbon atom is optionally replaced with a heteroatom.

8. The compound of claim 1 , wherein L 3 -Q is

wherein R comprises a QSY quencher or a QC-1 quencher; and

n is an integer from 1-8.

9. The compound of claim 8 , wherein the QSY quencher is a hydrophilic QSY quencher.

10. The compound of claim 9 , wherein the hydrophilic QSY quencher is a sulfo-QSY quencher.

11. The compound of claim 8 , wherein the QC-1 quencher has the structure:

12. The compound of claim 1 having the formula (III):

wherein R comprises a QSY quencher or a QC-1 quencher; and

m and n are independently integers from 1 to 8.

13. The compound of claim 12 , wherein R is

and D is

14. A compound having a structure according to the following formula, or a pharmaceutically acceptable salt thereof:

15. The compound according to claim 14 , wherein the pharmaceutically acceptable salt has a structure according to the following formula:

16. A composition for use in labeling a protease in an animal comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

17. A method of labeling a protease in an animal comprising the step of: administering the composition of claim 16 to the animal.

18. A method of visualizing a tumor in an animal comprising the steps of:

administering the composition of claim 16 to the animal; and

measuring a detectable signal generated in the animal from a reaction of the composition with a cathepsin cysteine protease;

where in the detectable signal is associated with a tumor in the animal.

19. The method of claim 18 , wherein the detectable signal is a fluorescent signal.

20. The method of claim 19 , wherein the fluorescent signal is generated at a tumor margin.

Assignments (2)
CONFIRMATORY LICENSE Recorded Jul 3, 2024
From: STANFORD UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 068121/0671 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 13, 2024
From: BOGYO, MATTHEW S.; VERDOES, MARTIJN
To: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Reel/Frame 067722/0244 →
Continuity (3)
Continuation 16338682
Provisional Application 62438959 · Dec 23, 2016
Related Publication 20210128753A1 · May 6, 2021